2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Treatment Considerations, Supportive Care, Non-Biological Therapies, Anticoagulant Drugs, Coagulant Drugs, Women’s Health, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

6146 Safety and efficiency of omitting the iron dextran test dose in first-time recipients

Daniel Valdes, PharmD, Marwan Shaikh, MD2, Amir Kayali, MD3, Treasure Bright, PharmD4
3 Mayo Clinic Florida, Jacksonville, Florida, United States
4 Mayo Clinic Florida, Jacksonville, Florida, United States

Iron dextran test doses are intended to identify patients at risk for anaphylaxis before full-dose administration; however, evidence supporting this practice is limited, and test doses may unnecessarily prolong infusion encounters. This retrospective pre-post cohort study evaluated the safety and operational impact of omitting the test dose during first-lifetime iron dextran administrations at a single outpatient infusion clinic at Mayo Clinic Florida. The pre-intervention cohort (January 2020–November 2022; n = 45) received a test dose per institutional protocol, whereas the post-intervention cohort (January 2023–October 2025; n = 433) received iron dextran without a test dose following a protocol change in December 2022. The primary outcome was the incidence of infusion-related reactions identified through chart review and medication administration records and graded using Common Terminology Criteria for Adverse Events version 6.0. Secondary outcomes included chair utilization ratio (actual chair time/scheduled chair time), encounter duration, reaction characteristics, and use of premedications and rescue interventions. Infusion reactions occurred in 6 of 45 patients (13.3%) in the test-dose cohort and 22 of 433 (5.1%) in the no-test-dose cohort (P = .056). Median encounter duration decreased from 200 to 135 minutes (P < .001), and median chair utilization ratio decreased from 1.67 to 1.12 (P < .001) following protocol implementation. Routine omission of the iron dextran test dose was not associated with an increased incidence of infusion-related reactions and significantly reduced encounter duration, supporting reconsideration of this longstanding practice.

Marwan Shaikh, MD: No relevant conflicts of interest to declare.